Sigma-Tau Pharmaceuticals, Inc. Receives FDA Approval of CYSTARAN(TM) (Cysteamine Ophthalmic Solution) 0.44% for Treatment of Corneal Cystine Crystals in Cystinosis Patients
October 04, 2012 07:24 ET
|
Sigma-Tau Pharmaceuticals
GAITHERSBURG, Md., Oct. 4, 2012 (GLOBE NEWSWIRE) -- Sigma-Tau Pharmaceuticals, Inc. announced today that the Company has received approval from the U.S. Food & Drug Administration ("FDA") for...